泌尿肿瘤学中的免疫检查点抑制剂：对生物标志物的迫切需求
Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers.
作者信息
Pichler Renate
机构信息
Department of Urology, Medical University Innsbruck, A-6020 Innsbruck, Austria.
出版信息
Cancers (Basel). 2020 Sep 27;12(10):2768. doi: 10.3390/cancers12102768.
Abstract
Bladder cancer and renal cell carcinoma (RCC) are the second and third most commonly diagnosed cancers in the field of uro-oncology [...].
摘要
膀胱癌和肾细胞癌（RCC）是泌尿肿瘤学领域中第二和第三大最常被诊断出的癌症[...]。
相似文献
1
Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers.泌尿肿瘤学中的免疫检查点抑制剂：对生物标志物的迫切需求
Cancers (Basel). 2020 Sep 27;12(10):2768. doi: 10.3390/cancers12102768.
2
[Renaissance of immuno-oncology for urological tumors : Current status].[泌尿肿瘤免疫肿瘤学的复兴：现状]
Urologe A. 2016 May;55(5):621-6. doi: 10.1007/s00120-016-0107-4.
3
Checkpoint inhibition: new treatment options in urologic cancer.检查点抑制：泌尿系统癌症的新治疗选择
Acta Clin Belg. 2017 Feb;72(1):24-28. doi: 10.1080/17843286.2016.1260890.
4
Application of Mass Spectrometry Imaging in Uro-Oncology: Discovering Potential Biomarkers.质谱成像在泌尿肿瘤学中的应用：发现潜在生物标志物
Life (Basel). 2022 Mar 3;12(3):366. doi: 10.3390/life12030366.
5
Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.酪氨酸激酶抑制剂在肾癌治疗中的应用进展。
Expert Rev Anticancer Ther. 2019 Mar;19(3):259-271. doi: 10.1080/14737140.2019.1573678. Epub 2019 Feb 4.
6
Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.酪氨酸激酶抑制剂对肾癌的治疗潜力及替代疗法的局限性
Ochsner J. 2019 Summer;19(2):138-151. doi: 10.31486/toj.18.0015.
7
Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.免疫原性化疗在临床前模型中使肾癌对免疫检查点阻断疗法敏感。
Med Sci Monit. 2017 Jul 11;23:3360-3366. doi: 10.12659/msm.902426.
8
Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.当前和未来新型免疫疗法在泌尿肿瘤学中的应用：文献综述的批判性评价。
Eur Urol Focus. 2018 Apr;4(3):442-454. doi: 10.1016/j.euf.2017.10.001. Epub 2017 Oct 19.
9
Recent advances in immuno-oncology and its application to urological cancers.免疫肿瘤学的最新进展及其在泌尿系统癌症中的应用。
BJU Int. 2016 Oct;118(4):506-14. doi: 10.1111/bju.13518. Epub 2016 Jun 3.
10
Immune checkpoint inhibition for the treatment of renal cell carcinoma.免疫检查点抑制治疗肾细胞癌。
Expert Opin Biol Ther. 2020 Jan;20(1):83-94. doi: 10.1080/14712598.2020.1677601. Epub 2019 Oct 13.
引用本文的文献
1
Identification of Novel Prognostic Signatures for Clear Cell Renal Cell Carcinoma Based on ceRNA Network Construction and Immune Infiltration Analysis.基于 ceRNA 网络构建和免疫浸润分析鉴定透明细胞肾细胞癌的新型预后标志物。
Dis Markers. 2022 Mar 14;2022:4033583. doi: 10.1155/2022/4033583. eCollection 2022.
2
Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌患者中竞争性内源性RNA网络的构建及与远处转移和不良预后相关的3个关键长链非编码RNA特征的验证
Front Oncol. 2021 Mar 24;11:640150. doi: 10.3389/fonc.2021.640150. eCollection 2021.
本文引用的文献
1
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.阿维鲁单抗维持治疗晚期或转移性尿路上皮癌。
N Engl J Med. 2020 Sep 24;383(13):1218-1230. doi: 10.1056/NEJMoa2002788. Epub 2020 Sep 18.
2
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肉瘤样肾细胞癌患者一线治疗的疗效和安全性。
Clin Cancer Res. 2021 Jan 1;27(1):78-86. doi: 10.1158/1078-0432.CCR-20-2063. Epub 2020 Sep 1.
3
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.阿特珠单抗联合或不联合化疗治疗转移性尿路上皮癌（IMvigor130）：一项多中心、随机、安慰剂对照的 3 期临床试验。
Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0.
4
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.免疫检查点抑制剂在泌尿系统癌症多学科管理中的安全使用：欧洲泌尿外科学会 2019 年立场。
Eur Urol. 2019 Sep;76(3):368-380. doi: 10.1016/j.eururo.2019.05.041. Epub 2019 Jun 21.
5
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
6
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.阿替利珠单抗单药或联合贝伐珠单抗与舒尼替尼治疗肾细胞癌的临床活性和分子相关性。
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
9
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
10
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.avelumab 联合 axitinib 作为晚期透明细胞肾细胞癌（JAVELIN Renal 100）一线治疗的初步结果：一项开放标签、剂量发现和剂量扩展的 1b 期试验。
Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.
Zotero 插件